Single-dose oral pharmacokinetics of pergolide mesylate in healthy adult mares.

This research article focuses on exploring the impact of the drug pergolide mesylate in addressing a common disease found in aging horses known as Pituitary pars intermedia dysfunction (PPID). The study primarily examines the drug’s pharmacokinetics, or how the drug is absorbed and processed by the body, in a group of healthy mares.

Background

• The study discusses Pituitary pars intermedia dysfunction (PPID), a disease commonly found in geriatric horses, which manifests various symptoms like hirsutism, excessive urination, immune suppression, muscle wasting, and laminitis.
• The standard treatment for PPID is pergolide, a type of dopamine agonist. Yet, despite its widespread usage, no pharmacokinetic data exists about this drug’s effects on horses.

Purpose of the Study

• This research attempts to fill the information gap regarding the pharmacokinetics of pergolide in horses.
• The study was conducted using a small group of relatively young and healthy mares to establish preliminary data that could serve as a basis for future larger-scale studies.

Future Research

• The researchers acknowledge that more in-depth studies are required to provide clinicians with definitive dosing recommendations.
• These future studies would need to evaluate the correlation between plasma pergolide concentrations and clinical outcomes.
• Moreover, they should examine the effect of various factors such as gender, age, and concurrent disease on the absorption and disposition of pergolide.